NasdaqCM:AXGN

Stock Analysis Report

Executive Summary

AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves.

Snowflake

Fundamentals

High growth potential with excellent balance sheet.

Risks

  • AxoGen has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has AxoGen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.3%

NasdaqCM:AXGN

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

-57.9%

NasdaqCM:AXGN

9.1%

US Medical Equipment

2.0%

US Market

AXGN underperformed the Medical Equipment industry which returned 8.7% over the past year.

AXGN underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

AXGNIndustryMarket
7 Day-7.3%-0.9%1.3%
30 Day-6.3%0.7%3.9%
90 Day-26.5%4.4%3.4%
1 Year-57.9%-57.9%10.0%9.1%4.2%2.0%
3 Year68.6%68.6%70.7%65.5%47.2%37.6%
5 Year526.6%526.6%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is AxoGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AxoGen undervalued based on future cash flows and its price relative to the stock market?

4.08x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for AxoGen to establish if it is available at moderate discount.

Unable to calculate intrinsic value for AxoGen to establish if it is available at substantial discount.


Price Based on Earnings

AxoGen is loss making, we can't compare its value to the US Medical Equipment industry average.

AxoGen is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for AxoGen, we can't assess if its growth is good value.


Price Based on Value of Assets

AxoGen is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is AxoGen expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

55.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

AxoGen's revenue is expected to grow significantly at over 20% yearly.

AxoGen's earnings are expected to grow significantly at over 20% yearly.

AxoGen's revenue growth is expected to exceed the United States of America market average.

AxoGen's earnings growth is expected to exceed the United States of America market average.

AxoGen's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if AxoGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has AxoGen performed over the past 5 years?

-7.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

AxoGen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare AxoGen's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare AxoGen's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if AxoGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if AxoGen has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if AxoGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is AxoGen's financial position?


Financial Position Analysis

AxoGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

AxoGen's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

AxoGen has no debt.

AxoGen currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

AxoGen has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

AxoGen has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if AxoGen has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is AxoGen's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate AxoGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate AxoGen's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as AxoGen has not reported any payouts.

Unable to verify if AxoGen's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as AxoGen has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of AxoGen's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Karen Zaderej (57yo)

8yrs

Tenure

US$3,665,188

Compensation

Ms. Karen Zaderej has been the Chief Executive Officer of AxoGen, Inc. since May 2010 and also has been its President since September 30, 2011. She has been Director of Viveve Medical Inc. since September  ...


CEO Compensation Analysis

Karen's remuneration is higher than average for companies of similar size in United States of America.

Karen's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.3yrs

Average Tenure

54.5yo

Average Age

The average tenure for the AxoGen management team is less than 2 years, this suggests a new team.


Board Age and Tenure

6.0yrs

Average Tenure

58.5yo

Average Age

The tenure for the AxoGen board of directors is about average.


Insider Trading

More shares have been bought than sold by AxoGen individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$52,38915 Aug 19
Mark Gold
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,000
Max PriceUS$13.13
BuyUS$85,13914 Aug 19
Isabelle Billet
EntityIndividual
Role
Senior Key Executive
Chief Strategy & Business Development Officer
Shares5,635
Max PriceUS$15.12
BuyUS$30,26014 Aug 19
Maria Martinez
EntityIndividual
Role
Head of Human Resources
Chief Human Resources Officer
Shares2,000
Max PriceUS$15.13
BuyUS$217,67313 Aug 19
Quentin Blackford
EntityIndividual
Role
Member of the Board of Directors
Director
Shares15,535
Max PriceUS$14.10
BuyUS$1,012,42512 Aug 19
Karen Zaderej
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares75,000
Max PriceUS$13.50
BuyUS$101,25014 Jun 19
Amy McBride-Wendell
EntityIndividual
Shares5,000
Max PriceUS$20.25
SellUS$452,60017 May 19
David Hansen
EntityIndividual
Shares20,000
Max PriceUS$22.63
SellUS$645,00015 Nov 18
Gregory Freitag
EntityIndividual
Role
Member of the Board of Directors
General Counsel & Director
Shares20,000
Max PriceUS$32.25
SellUS$829,62015 Nov 18
Karen Zaderej
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares25,000
Max PriceUS$33.42

Ownership Breakdown


Management Team

  • Greg Freitag (57yo)

    General Counsel & Director

    • Tenure: 8yrs
    • Compensation: US$856.65k
  • Pete Mariani (55yo)

    Chief Financial Officer

    • Tenure: 3.5yrs
    • Compensation: US$1.44m
  • Karen Zaderej (57yo)

    Chairman

    • Tenure: 8yrs
    • Compensation: US$3.67m
  • Eric Sandberg (54yo)

    Chief Commercial Officer

    • Tenure: 0.7yrs
  • Mike Donovan (54yo)

    Vice President of Operations

    • Tenure: 4yrs
  • Maria Martinez (51yo)

    Chief Human Resources Officer

    • Tenure: 0.9yrs
  • Kaila Krum

    Vice President of Investor Relations & Corporate Development

    • Tenure: 1.3yrs
  • Greg Davault (51yo)

    Vice President of Marketing

    • Tenure: 1.3yrs
  • Isabelle Billet (57yo)

    Chief Strategy & Business Development Officer

    • Tenure: 0.9yrs
  • John Glueck

    Chief Compliance Officer & Assistant General Counsel

    • Tenure: 0.9yrs

Board Members

  • Guido Neels (71yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$169.90k
  • Greg Freitag (57yo)

    General Counsel & Director

    • Tenure: 8yrs
    • Compensation: US$856.65k
  • James Grooms (59yo)

    Director

    • Tenure: 8yrs
    • Compensation: US$174.90k
  • Robert Rudelius (63yo)

    Director

    • Tenure: 9yrs
    • Compensation: US$182.40k
  • Mark Gold (69yo)

    Director

    • Tenure: 8yrs
    • Compensation: US$179.90k
  • Bruce Mast

    Member of Board of Advisor

    • Tenure: 0yrs
  • Karen Zaderej (57yo)

    Chairman

    • Tenure: 8yrs
    • Compensation: US$3.67m
  • David Muir

    Member of Board of Advisor

    • Tenure: 0yrs
  • Quentin Blackford (40yo)

    Director

    • Tenure: 0.3yrs
  • Amy Wendell (58yo)

    Lead Director

    • Tenure: 1.3yrs
    • Compensation: US$164.90k

Company Information

AxoGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AxoGen, Inc.
  • Ticker: AXGN
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$563.310m
  • Shares outstanding: 39.26m
  • Website: https://www.axogeninc.com

Number of Employees


Location

  • AxoGen, Inc.
  • 13631 Progress Boulevard
  • Suite 400
  • Alachua
  • Florida
  • 32615
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXGNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2011
LT3DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011
0HKDLSE (London Stock Exchange)YesCommon StockGBUSDOct 2011

Biography

AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerv ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:16
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.